Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, P. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, P. E.
American Journal of Health-System Pharmacy, Vol. 65, Issue 2 Supplement 1, S4-S10
Copyright © 2008. American Society of Health-System Pharmacists, Inc. All rights reserved. 1079-2082/04/0602-1242$06.00

Pharmaceutical reimbursement: An overview

Philip E. Johnson

PHILIP E. JOHNSON, M.S., R.PH., FASHP, is Director of Pharmacy, H. Lee Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612-9497 (Johnson{at}moffitt.usf.edu).


Purpose. The Medicare program authority, structure, and current and proposed rules for and rates of pharmaceutical reimbursement; billing issues; proposed expansion of accepted compendia and off-label drug uses; problems with the cost basis for reimbursement; concerns of and need for collaboration among various participants in the health care revenue stream; and implications for pharmacists are described.

Summary. Pharmaceutical reimbursement rates have decreased over the past several years as the Centers for Medicare and Medicaid Services (CMS) has striven to maintain neutrality in the federal budget. Now, health systems that fail to report quality indicators can incur financial penalties. Also, smaller payments for cases involving medical errors have been proposed. Efforts by pharmacists to improve the billing process can increase revenue. It is anticipated that rules proposed for 2008 will result in CMS acceptance of a greater number of compendia and off-label uses. Receiving reimbursement for drug handling costs is an important issue for pharmacists. Collaboration among pharmacists and other participants in the health care revenue stream is needed to improve the health care delivery system and ensure that money is wisely spent.

Conclusion. An understanding of the complexities of Medicare pharmaceutical reimbursement can help pharmacists improve the financial viability of their institutions.

Index terms: Billing; Costs; Drugs; Health-benefit programs; Pharmacists; Pharmacy; Regulations; Reimbursement

 



This article has been cited by other articles:


Home page
Annals of Clinical & Laboratory ScienceHome page
E. Stevens, B. F. Kimler, M. K. Davis, F. Fan, P. Thomas, X.-Y. Wang, I. Damjanov, and O. W. Tawfik
A Newly Proposed Semi-Automated Method of Grading Invasive Lobular Carcinoma: A Unifying Concept and Correlation with Prognostic Markers and Patient Survival
Ann. Clin. Lab. Sci., January 1, 2009; 39(1): 25 - 31.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Society of Health-System Pharmacists.